<DOC>
	<DOC>NCT01497574</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents with type 1 diabetes.</brief_summary>
	<brief_title>Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes for at least 12 months Body mass index (BMI) for children (6 to 12 years): 1520 kg/m^2 (both inclusive) Body mass index (BMI) for adolescents (13 to 17 years): 1825 kg/m^2 (both inclusive) HbA1c (glycosylated haemoglobin) below 11.0% according to central laboratory results Current treatment with insulin at least twice daily Any significant disease such as endocrine, hepatic, renal, cardiac, neurological, malignant, or pancreatic disease other than diabetes Receipt of any investigational product within the last four weeks Known or suspected allergy to trial products or related products</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>